by barry101 | Apr 14, 2021 | Press Releases
HOUSTON, April 14, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced...
by barry101 | Apr 6, 2021 | Press Releases
HOUSTON, April 6, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the engagement of IQVIA...
by barry101 | Mar 30, 2021 | Press Releases
HOUSTON, March 30, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and...
by barry101 | Mar 24, 2021 | Press Releases
HOUSTON, March 24, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results...
by barry101 | Mar 9, 2021 | Press Releases
HOUSTON, March 9, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of...
by barry101 | Feb 10, 2021 | Press Releases
Increases Gross Proceeds to Approximately $78 MillionHOUSTON, Feb. 10, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
